Pfizer Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 383 Posts
1 2 3 ... 24
Undervalued Growth And Dividend Growth In Health Technology
Article By: Chuck Carnevale Wednesday, March 20, 2019 11:13 AM EDT
Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015.
Pfizer Prices US$5bn Bond As Corporate Debt Deluge Continues
Article By: Interactive Brokers Tuesday, March 5, 2019 3:00 PM EDT
Pfizer said it will peg proceeds from the sale for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper.
In this article: PFE Also: GSK, XLV, SPX, BMY, CELG, JUNO
E Daily Stock Pick: Pfizer Inc
Article By: Fredrik Arnold Tuesday, February 26, 2019 5:22 AM EDT
Pfizer's price per share closed at $43.33 yesterday. A year ago its price was $36.26. Price rose $41.52 per share last year, or almost 19.5%.
In this article: PFE
Dogs Of The Dow And A 3 Top Dogs Strategy
Article By: Sunday, February 17, 2019 10:12 AM EDT
The “Dogs of the Dow” is one of the simplest, most well-known dividend strategies on Wall Street. And investors who choose to jump in during 2019 will be shooting for their fifth straight year of market-beating returns.
In this article: CVX, IBM, JPM, KO, MRK, PFE, PG, VZ, XOM, CSCO
Wall Street's Top Stories For Tuesday, Jan. 29th
Article By: The Fly Tuesday, January 29, 2019 4:08 PM EDT
Stocks have mixed day as investors await Apple earnings.
Pfizer Q4 Earnings & Sales Beat, 2019 View Disappoints
Article By: Zacks Investment Research Tuesday, January 29, 2019 10:51 AM EDT
PFE beat fourth-quarter earnings which came in at 64 cents.
In this article: PFE
The 8 'Dogs Of The Dow' For 2019 Include Replacements Cisco Systems And JPMorgan
Article By: Richard Suttmeier Monday, January 7, 2019 5:50 PM EDT
The eight “Dogs of the Dow” for 2018 outperformed the Dow Jones Industrial Average in 2018. Now here are my picks for 2019.
In this article: CVX, MRK, PG, CSCO, IBM, JPM, KO, PFE, VZ, XOM
The “New Year” Starts With A Rally
Article By: Lance Roberts Saturday, January 5, 2019 6:12 PM EDT
While, at this point, the risk/reward for traders remains on the “bullish” side, the economic warnings from Fed Ex, Apple, and the economic surveys should not be dismissed.
In this article: AEP, DUK, FDX, MDT, PEP, PFE, V, VZ, AAPL, MSFT, SPY
The Santa Rally Left Much To Be Desired
Article By: Lance Roberts Saturday, December 29, 2018 4:42 PM EDT
The market did finally muster a rally last week but did little to reverse any of the technical damage done over the last month. The rally was simply an oversold, short-covering, bounce that left much to be desired in terms of commitment.
In this article: GE, PFE, V, MSFT, SPY, ABBV, GDX
Latest Dividend Increases December 2018
Article By: Andreas Gruener Sunday, December 23, 2018 2:10 AM EDT
Dividend increases are a wonderful thing and the main drive why we do dividend investing. The secret is to find the right balance of high yield stocks with a rather slow dividend increase per year and lower yield stocks. Here are my picks.
In this article: T, PFE Also: CSCO, MO, ABBV, GIS, GKNGY, GRKGF
Pfizer, GSK To Merge Consumer Healthcare Units Into Joint Venture
Article By: The Fly Wednesday, December 19, 2018 11:27 AM EDT
Pfizer and GlaxoSmithKline announced they have entered into an agreement to create a consumer healthcare company.
In this article: GSK, PFE
Thirteen Companies Boosting Distributions For Long-Term Shareholders
Article By: Dividend Growth Investor Monday, December 17, 2018 1:16 PM EDT
An increase that is well below the rate of dividend growth indicates caution, while an increase that is close to or higher than the average indicates optimism.
In this article: O, BEN, T, AMGN, ERIE, GGG, THG, PFE, ABT, D, UBA, WM, VTR
Exact Sciences: Poised For Further Growth
Article By: TipRanks Sunday, November 4, 2018 3:17 PM EDT
Exact Sciences is moving forward on a solid foundation: a proven product, a new marketing initiative to expand – or even double – its reach. It’s no surprise that every analyst who has reviewed EXAS recently has given it a ‘Buy’ rating
In this article: PFE, EXAS
A Drug Giant Whose Dividend Safety Isn’t As Bad As It Looks
Article By: Marc Lichtenfeld Wednesday, October 10, 2018 7:30 PM EDT
Investors tend to buy large pharmaceutical companies because of their safety.
In this article: PFE
AI And The New Health Care
Article By: John Thomas Friday, September 28, 2018 3:34 AM EDT
The first major industry to be fundamentally disrupted by AI will be health care. The next step in our intellectual evolution will be carried out by AI. By connecting our neocortex to the Internet, we will greatly improve our intelligence.
In this article: BMY, MRK, PFE, XLV, XPH
Week In Review: Three More China Biopharmas Planning Hong Kong IPOs
Article By: ChinaBio® Today Saturday, August 25, 2018 4:14 PM EDT
Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters.
In this article: BNY, PFE, CBPO, BGNE, ZLAB
1 to 16 of 383 Posts
1 2 3 ... 24